Profound Medical Wins INOVAIT’s Mount Logan Award for TULSA Procedure

Event summary

  • Profound Medical received INOVAIT’s 2025–2026 Mount Logan Award for its TULSA Procedure.
  • The company has treated 4,000 patients with the TULSA Procedure and secured new U.S. reimbursement codes from Medicare.
  • Profound Medical regained exclusive distribution rights in Canada and is deploying a direct sales team in North America.
  • The TULSA-PRO system is CE marked, Health Canada approved, and FDA 510(k) cleared.

The big picture

Profound Medical’s recognition by INOVAIT underscores its leadership in interventional MRI procedures, particularly for prostate disease. The company’s strategic moves, including securing new reimbursement codes and expanding its sales efforts, position it to capitalize on the growing demand for minimally invasive, precision-driven treatments. The TULSA Procedure’s ability to preserve patient quality of life while offering a one-and-done solution aligns with broader industry trends toward personalized and efficient medical interventions.

What we're watching

Commercial Expansion
How Profound Medical’s direct sales team deployment and strategic partnerships will impact global commercialization.
Regulatory Dynamics
Whether the new U.S. reimbursement codes will drive broader adoption of the TULSA Procedure.
Technology Adoption
The pace at which the TULSA-PRO system will be adopted in Canada following the regain of exclusive distribution rights.

Related topics

Medical Devices